The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.
The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therapeutic interventions that may result in protective, CTL-based antitumor immunity.
Lindauer
M
M
Johannes Gutenberg University, III. Medizinische Klinik, Department of Hematology, Mainz, Germany.
Stanislawski
T
T
Häussler
A
A
Antunes
E
E
Cellary
A
A
Huber
C
C
Theobald
M
M
D000595:Amino Acid Sequence; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D019496:Cancer Vaccines